Brit J Cancer: Prognosis of preoperative and postoperative tumor markers in patients with stomach cancer

In clinical practice, cancer embryo antigen (CEA) and CA19-9 are the most commonly measured markers before and after gastric cancer (GC) surgeryHowever, it is not clear whether preoperative or postoperative joint tumor markers (CEA and CA19-9) have greater prognosis valuerecently published a research paper in British Journal of Cancer, an authoritative journal of the field of oncology, in which researchers included the prognostic effects of patients who had a GC excision at Concord Hospital in Fujian Medical University between January 2011 and December 2014, and used Kaplan-Meier logarithus arithmetic survival analysis and multivariable Cox regression analysis to assess the prognostic effects of tumor markers before and after surgeryThe results are then externally validatedidentified 735 and 400 patients in the discovery and validation queues, respectivelyThe overall survival rate was gradually reduced in relation to the number of preoperative and postoperative positive tumor markers (all P 0.001)The multivariate analysis showed that the number of preoperative positive tumor markers was an independent prognosis (P 0.05)For patients with abnormal preoperative tumor markers, the normalization of postoperative tumor markers is an independent prognostic protective factor (risk ratio (HR) s 0.618; 95% confidence interval (CI) is 0.414-0.921), and the total risk of death in patients who are positive for both postoperative tumor markers (HR s 2.338; 95% CI is 1.071-5.1.1.0001)Similar results were observed in the internal and external validation queuesthus show that preoperative tumor markers have a better ability to distinguish between postoperative survival of GC patients than postoperative tumor markers, and tumor markers are normalized after surgery and better patient survival